# Spirea

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spirea

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.spirea.co.uk
- Latest round: Seed (Jul 13, 2020)
- Investors on record: 2

## About

Founded in 2017 by its CEO, Myriam Ouberai, and based in Cambridge, UK, Spirea Ltd., operates as a biotechnology company that develops antibody-drug conjugates for cancer treatments. In June 2022, Spirea Ltd., raised GBP 2.36 million in venture funding, co-led by an individual investor and returning investor Cambridge Enterprise, with participation from other returning investors from O2h Ventures and SyndicateRoom.

The company offers therapeutic solutions used for cancer treatment along with real-time data analysis solutions to optimize the efficacy and safety of ADC therapies. They collaborate with renowned hospitals and medical institutions to conduct clinical trials and validate their innovative ADC platform. The company’s technology specifically targets and destroys cancer cells, minimizing side effects and improving treatment outcomes.

The company plans to use the June 2022 funding to initiate its pipeline of differentiated ADCs for the treatment of solid tumours.

## Funding rounds

- Seed, Jul 13, 2020 — Start Codon, Meltwind

## Investors

- Start Codon (https://capitalatlas.ai/funds/start-codon) — Seed
- Meltwind — Seed